ReviewNature reviews. Urology2010
Urine biomarkers in prostate cancer.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles.Journal of extracellular vesicles · 2021Guideline
- The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Cost-Effective and User-Friendly Pencil Graphite Electrode Immunosensor for Label-Free Detection of Carcinoembryonic Antigen.Biotechnology and applied biochemistry · 2026Article
- Microfluidic paper-based analytical extraction devices (µPAEDs): a cost-effective and portable solution for biomarkers, contaminants and VOC detection.Mikrochimica acta · 2025Review
- STModule: identifying tissue modules to uncover spatial components and characteristics of transcriptomic landscapes.Genome medicine · 2025Article
- Towards Understanding the Role of the Glycosylation of Proteins Present in Extracellular Vesicles in Urinary Tract Diseases: Contributions to Cancer and Beyond.Molecules (Basel, Switzerland) · 2024Review
- Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer.Cancer cell international · 2023Review
- Biomolecular sensors for advanced physiological monitoring.Nature reviews bioengineering · 2023Review
- Aptamer-antibody hybrid ELONA that uses hybridization chain reaction to detect a urinary biomarker EN2 for bladder and prostate cancer.Scientific reports · 2022Article
- Standard-free single magnetic bead evaluation: a stable nanoplatform for prostate disease differentiation.Chemical science · 2022Article
- Nephron mass determines the excretion rate of urinary extracellular vesicles.Journal of extracellular vesicles · 2022Article
- The Comprehensive Analysis of Hub Gene ARRB2 in Prostate Cancer.Disease markers · 2022Article
- Using human urinary extracellular vesicles to study physiological and pathophysiological states and regulation of the sodium chloride cotransporter.Frontiers in endocrinology · 2022Review
- Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis.Frontiers in immunology · 2022Article
- Long Noncoding RNA NEAT1 as a Potential Candidate Biomarker for Prostate Cancer.Life (Basel, Switzerland) · 2021Article
- A Comprehensive Urine Proteome Database Generated From Patients With Various Renal Conditions and Prostate Cancer.Frontiers in medicine · 2021Article
- A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.Investigative and clinical urology · 2020Article
- Mapping human N-linked glycoproteins and glycosylation sites using mass spectrometry.Trends in analytical chemistry : TRAC · 2019Article
- Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.Nature reviews. Urology · 2019Review
- Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The deficiencies of serum PSA as a prostate-cancer-specific diagnostic test are well recognized. Thus, the development of novel biomarkers for prostate cancer detection remains an important and exciting challenge. Noninvasive urine-based tests are particularly attractive candidates for large-scale screening protocols, and biomarker discovery programs using urine samples have emerged for detecting and predicting aggressiveness of prostate cancer. Some new biomarkers already outperform serum PSA in the diagnosis of this disease. Currently, the PCA3 (prostate cancer antigen 3) urine test is probably the best adjunct to serum PSA for predicting biopsy outcome, and has proven its clinical relevance by surpassing the predictive abilities of traditional serum biomarkers. New research methods are also emerging, and high-throughput technologies will facilitate high-dimensional biomarker discovery. Future approaches will probably integrate proteomic, transcriptomic and multiplex approaches to detect novel biomarkers, and aim to identify combinations of multiple biomarkers to optimize the detection of prostate cancer. In addition, an unmet need remains for markers that differentiate indolent from aggressive cancers, to better inform treatment decisions.
Indexed as
Identifiers
20065953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.